Articles By Janet Pope, MD, MPH, FRCPC
How are RA patients doing using telemedicine/virtual care?
Rheumatologists switched their practices overnight from primarily in person to nearly all virtual care as COVID-19 pandemic geared up in March 2020 and then to a blend of in person and virtual care. How are RA patients doing?
Read Article
What’s new in knee osteoarthritis that matters?
Are intra-articular steroid injections effective in symptomatic knee OA? Do they accelerate cartilage loss? Does weight less actually help? Do we have DMARDs for knee OA? Insights from 2020 ACR Convergence.
Read Article
Link Between Obstructive Lung Disease and Developing RA?
We all know that the microbiome in the gut may be very important for multiple immune diseases. However, new findings from the ACR, 2019 in Atlanta reinforce how important the interface is between the lungs and developing rheumatoid arthritis.
Read Article
Be ‘on point’: Guidelines for rheumatic complications of immunotherapy
Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.
Read Article
Blinded by the Use of Antimalarials in Lupus?
Editor's note: July 1 - 5, RheumNow is running the best of EULAR 2019 meeting. Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR gui
Read Article
Blinded by the Use of Antimalarials in Lupus?
Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD.
Read Article
Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?
Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).
Read Article
We Measure What we do in RA, But so What?
We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change.
Read Article
Does RA kill you? Let me count the ways….and what you can do about it
There were many presentations at EULAR 2018 in Amsterdam about the mortality of RA.
Read Article
